Mol Carcinog 2010, 49:68–74.PubMed 32. Herzer K, Hofmann T, Teufel A, Schimanski C, Moehler M, Kanzler S, Schulze-Bergkamen H, Galle P: IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic Sapanisertib clinical trial leukemia protein and TRAIL independently of p53. Cancer Res 2009, 69:855–862.PubMedCrossRef 33. Lim dY, Jeong Y, Tyner A, Park J: Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound

luteolin. Am J Physiol Gastrointest Liver Physiol 2007, 292:G66-G75.CrossRef 34. Bekisz J, Baron S, Balinsky C, Morrow A, Zoon K: Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals (Basel) 2010, 3:994–1015.CrossRef 35. Hagiwara S, Kudo M, Ueshima K, Chung H, Yamaguchi M, Takita M, Haji S, Kimura M, Arao T, Nishio K, Park A, Munakata H: The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon alpha-2b therapy against advanced hepatocellular carcinoma. J Gastroenterol 2010, 46:212–221.PubMedCrossRef 36. Su W, Liu W, Cheng C, Chou Y, Hung K, Huang W, Wu C, Li Y, Shiau A, Lai M: Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities. FEBS Lett 2009, 583:2793–2798.PubMedCrossRef 37. García A, Morales P, Rafter J, Haza A: N-Nitrosopiperidine

and N-Nitrosodibutylamine induce apoptosis in HepG2 cells via the caspase dependent pathway. Cell Biol ��-Nicotinamide ic50 Int 2009, 33:1280–1286.PubMedCrossRef 38. Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G: Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer 2012,  . 39. Ceballos MP, Parody JP, Alvarez ML, Ingaramo PI, Carnovale CE, Carrillo MC: Interferon-α2b and transforming growth factor-β1 treatments on HCC cell lines: Are Wnt/β-catenin pathway and Smads signaling connected in hepatocellular carcinoma?

Biochem Pharmacol 2011, 82:1682–1691.PubMedCrossRef 40. Thompson MD, Dar MJ, Monga SP: Pegylated interferon alpha targets Wnt signaling Avelestat (AZD9668) by inducing nuclear export of β-catenin. J Hepatol 2011, 54:506–512.PubMedCrossRef 41. North TE, Babu IR, Vedder LM, Lord AM, Wishnok JS, Tannenbaum SR, Zon LI, Goessling W: PGE2-regulated wnt signaling and N-acetylcysteine are synergistically hepatoprotective in zebrafish acetaminophen injury. Proc Natl Acad Sci U S A 2010, 107:17315–17320.PubMedCrossRef 42. Zhou M, Gu L, Zhu N, Woods W, Findley H: Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53. Oncogene 2003, 22:8137–8144.PubMedCrossRef 43. Baud V, Karin M: Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009, 8:33–40.PubMedCrossRef 44. Jost P, Ruland J: Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007, 109:2700–2707.PubMed 45.